CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.9250
+0.0349 (3.92%)
At close: Apr 28, 2025, 4:00 PM
0.9308
+0.0058 (0.63%)
Pre-market: Apr 29, 2025, 7:31 AM EDT
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Christopher Ehrlich |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
| Phone | 215 731 9450 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer and Chair |
| Dr. Lawrence Corey M.D. | Co-founder and Head of Scientific Advisory Board |
| Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | 10-K/A | [Amend] Annual report |
| Apr 25, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 10-K | Annual Report |
| Apr 4, 2025 | SCHEDULE 13D/A | Filing |
| Apr 1, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 13, 2025 | 424B3 | Prospectus |
| Feb 13, 2025 | 424B3 | Prospectus |
| Feb 13, 2025 | 424B3 | Prospectus |